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Sickle cell disease is a single amino acid molecular disorder of hemoglobin leading to its pathological
polymerization, red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia
and infarction. The manifestations of this disease are protean. Among them, leg ulcers represent a
particularly disabling and chronic complication, often associated with a more severe clinical course. Despite
the fact that this complication has been recognized since the early times of SCD, there has been little
improvement in the efficacy of its management and clinical outcome over the past 100 years. Recently,
vasculopathic abnormalities involving abnormal vascular tone and activated, adhesive endothelium have
been recognized as another pathway to end organ damage in sickle cell disease. Vasculopathy of sickle cell
disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and
priapism, particularly associated with hemolytic severity, and reported in other severe hemolytic disorders.
The authors present the proceedings from the Educational Session on Chronic leg ulcers in Sickle cell
disease, held during the 4th Annual Sickle Cell Disease Research and Educational Symposium, on February
17, 2010 in Fort Lauderdale, Fla.
The clinical manifestations of sickle cell disease (SCD) are diverse. Among them, leg ulcers are relatively common
and can be disabling. Leg ulcerations have been a long recognized complication of SCD and even the first SCD
patient to be described in North America in 1910 had chronic leg ulcerations [1, 2]. The prevalence of leg ulceration
varies, being low before age 10 years. It is most common in sickle cell anemia (homozygosity for HBB glu6val; HbSS)
and less often seen in HbSC disease or HbS-β thalassemia. Its geographical distribution is also variable, affecting
75% of HbSS patients in Jamaica but only 8–10% of North American patients [3–5]. The pathogenesis of chronic

ulcers in SCD is complex. Mechanical obstruction by dense sickled red cells, venous incompetence, bacterial
infections, abnormal autonomic control with excessive vasoconstriction when in the dependent position, in situ
thrombosis, anemia with decrease in oxygen carrying capacity, and decreased nitric oxide bioavailability leading to
impaired endothelial function have all been proposed as potential contributing factors [6, 7].
Venographic studies have shown that venous insufficiency is not a primary cause of sickle cell ulcerations. Instead, it
is the arteriovenous shunting, which has been postulated as a factor in ulcer formation. This shunting deprives the
skin of oxygen promoting ulceration. Furthermore, trauma, infection, and inflammation have all been cited as potential
causes of lower extremity ulcerations in SCD. It is the combination of these factors, along with the interrupted
microcirculation that contribute to the pathophysiology of lower extremity ulcerations in patients with SCD.
Leg ulcers occur in areas with less subcutaneous fat, thin skin, and with decreased blood flow [8]. The commonest
sites are the medial and lateral malleoli (ankles), often becoming circumferential if not controlled early; the medial
malleolus is more commonly involved than the lateral malleolus. Less common sites are the anterior tibial area,
dorsum of the foot, and Achilles tendon [9].

Severity Index

Many severity indices for leg ulcers are based on size, depth, and duration. Staging based on depth is as follows:
Stage 1: Nonblanchable erythema of intact skin, the heralding lesion of skin ulceration. In individuals with darker
skin, discoloration of the skin, warmth, edema, induration, or hardness may also be indicators.
Stage 2: Partial-thickness skin loss involving epidermis, dermis, or both. The ulcer is superficial and presents
clinically as an abrasion, blister, or shallow crater.
Stage 3: Full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to,
but not through, underlying fascia. The ulcer presents clinically as a deep crater with or without undermining of
adjacent tissue.
Stage 4: Full-thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle, bone, or
supporting structures (e.g., tendon and joint capsule). Undermining and sinus tracts also may be present.
Classification
Leg ulcers may be classified as acute or chronic according to their duration, however, there is no consensus as to a
specific length of time to define chronicity. An acute ulcer usually heals in less than a month. Among chronic ulcers,
duration of 6 months seems to define the most recalcitrant ulcers. It is not uncommon for ulcers to last many years,
often closing and reopening repeated times.
Clinical Features

Leg ulcers are painful and often. They tend to be indolent, intractable, and heal slowly over months to years. The pain
may be severe, excruciating, penetrating, sharp, and stinging in nature. In most patients, oral or parenteral opioid
analgesics are needed to achieve some pain relief. Leg ulcers are more common in males in some studies and their
incidence increases with age. Their association with the severity of hemolysis is suggested by their reduced
incidence in carriers of coincident α-thalassemia, individuals with higher hemoglobin concentrations and those with
high levels of HbF [5]. They are also associated with priapism and pulmonary hypertension, both felt to be markers of
advanced sickle vasculopathy. Moreover, leg ulcers have been reported to be more common in carriers of the CAR βglobin gene cluster haplotype.
Management
Treatment of leg ulcers includes wound care using wet to dry dressings. With regular and good localized treatment,
many small ulcers may heal within a few months. Leg ulcers that persist beyond 6 months may require other
modalities including, among other things, blood transfusion, skin grafting, Unna boots, zinc sulphate, hyperbaric
oxygen, arginine butyrate, topical herbal applications, topical growth factors. Unfortunately, success or failure of these
measures has been anecdotal in nature without the advantage of controlled clinical trials to identify the best approach
to management.
Principles of management of leg ulcers include education, protection, infection control, debridement, and
compression bandages. Debridement could be surgical, medical, or biological. Osteomyelitis may complicate chronic
leg ulcers, especially those with deep wounds, and it is advisable to rule out this complication with a bone scan or
MRI and bone biopsy if needed. Rarely, a leg ulcer is the cause of systemic infections, and occasional deaths
attributable to sepsis secondary to a leg ulcer infection have been reported. Also exceedingly rare is the need for
amputation of the leg or the foot affected by the ulcer.
Recent advances in the management of leg ulcers include topical applications of analgesics, including opioids for
pain, topical application of a platelet-derived growth factor prepared either autologously (Procuren) or by recombinant
technology (Regranex), and the use of cultured skin grafts. The use of semipermeable polymeric membrane dressing
seems to promote healing in diabetic foot ulcers. Moreover, manuka honey (from New Zealand) has been reported to
heal diabetic foot ulcers.
The role of hydroxyurea in the treatment of sickle leg ulcers is presently unclear, however, the weight of evidence
suggests the hydroxyurea does not cause, prevent, or speed healing of ulcers in SCD. Chronic transfusion has been
advocated for treatment of sickle leg ulcers; however, there is no systematic or controlled data that shows its efficacy.
Although it is common for the ulcer to heal when D transfusion therapy is initiated, they often recur when it is stopped.
Prevention

Old studies of nutritional deficiencies in SCD demonstrated that zinc deficiency is common in individuals with SCD.
The mineral is thought to play an important role in immune function and wound healing. Early, small but randomized
studies showed that administration of zinc sulfate 220 mg three times a day resulted in more rapid healing of leg
ulcers [10].
Clinical observations and epidemiological studies document the important role of local trauma in the onset of leg
ulcers. This provides a number of simple interventions that can be taught to older children and young adults, which
will potentially reduce the prevalence of this troubling complication, such as protective legging with nonelastic lower
extremity orthoses with ankle straps, to be worn during working hours. Educational interventions should be targeted
to health professionals so that the lower extremities are avoided as sites for venipuncture and vascular access unless
absolutely necessary. Although not all studies support the importance of venous stasis in the development of leg
ulcers, the most systematic epidemiological studies and clinical experience suggest that this may be a major
determinant of the success of treatment and prevention. Control of venous stasis requires behavioral modification,
may result in need for occupational rehabilitation, and may be common to all successful interventions. Venous stasis
may also explain the causal link between pulmonary hypertension and occurrence of leg ulcers. Bed rest and in
general limiting the amount of standing time seems to have an impact on wound healing as well.
Finally, epidemiological studies from Jamaica suggest that socioeconomic status has a major effect on the frequency
of leg ulcers in their cohort study.

Linkage of Leg Ulcers to Hemolysis-Associated Pulmonary Hypertension in Adults with SCD
Recent evidence suggests that patients with SCD and leg ulcers may be also at risk to develop other, much more
serious disease complications such as pulmonary hypertension, defined by tricuspid regurgitant velocity (TRV), and
high NT-proBNP levels, priapism and, possibly renal disease. Taylor et al. analyzed a large sample of patients, which
included the NIH data base and the cooperative study of SCD (CSSD) database and found that hyperhemolysis
subjects, defined by the top quartile of serum LDH level, had a higher prevalence of leg ulcers (OR 3.27, 95% CI
1.92–5.53, P < 0.0001), priapism (OR 2.62, 95% CI 1.13–6.90, P = 0.03), and pulmonary hypertension (OR 4.32,
95% CI 2.12–8.60, P < 0.0001), whereas osteonecrosis (OR 0.32, 95% CI 0.19–0.54, P < 0.0001) and pain (OR 0.23,
95% CI 0.09–0.55, P = 0.0004) were less prevalent [11]. Hyperhemolysis was influenced by HbF and alfa
thalassemia and was a risk factor for early death in the larger CSSCD population (Hazard Ratio = 1.97, P = 0.02). De
Castro et al. reported that 37% of HbSS patients with pulmonary hypertension defined by TRV had an history of
chronic leg ulcers compared with 15% of those without increased TRV [12]. More recently, a Turkish group reported
on the results of Echo Doppler analysis on of 88 HbSS patients; 12 patients (10 males, 2 females) had active ulcer or
healed scar (group I) and 76 patients (40 males, 36 females) had no active leg ulcer or history of (group II). The
prevalence of pulmonary hypertension in group I and group II was 91.6% (n = 11) and 31.6% (n = 24), respectively (P

= 0.0001). Patients with leg ulceration had increased left atrium and right ventricular diameters at diastole and also
had increased left ventricular end-diastolic and end-systolic diameters. They concluded that patients with HbSS,
especially those with leg ulcers should be screened for pulmonary hypertension.
We have recently examined an NIH cohort of almost 400 adult patients and found that 18% of all subjects had a
history of leg ulceration (21.4% of HbSS and 9.6% of HbSC patients). Table I Patients affected were older, had
markers of significantly more severe hemolysis, high serum uric acid, alkaline phosphatase, NT-proBNP, and lower
serum albumin. They had a significantly higher prevalence of elevated TRV, suggestive of pulmonary hypertension
(Fig. 1). Significantly, patients with a history of leg ulcers were more likely to have died by the time of data analysis
(21% vs. 9%, P = 0.02), with a similar trend on Kaplan–Meier analysis (Fig. 2). None of the other parameters
evaluated were significantly associated with leg ulceration, including history of pain, acute chest syndrome, stroke, or
priapism. Patients on hydroxyurea therapy or chronic transfusions did not have a lower incidence of leg ulcers, and
HbF was not protective.

Figure 1. Prevalence of elevated TRV among study participants by
history of leg ulcers. P value from Chi-square test of independence
between grouped TRV and history of leg ulcers (yes/no).

Table I. Characteristics of Study Participants by History of Leg Ulcers, NIH Sickle Cell Cohort

No leg ulcers

Characteristic

Age (years)
Yes

History of leg ulcers

N

Median (IQR)a

N

Median (IQR)

P Valueb

325

31 (25–42)

71

42 (32–49)

<0.0001

118

30

Chronic transfusions

0.3
No

Hydroxyurea treatment, N (%)

171
317

32
123 (39%)

71

25 (35%)

0.6

≥2.5

122

38

0.02

>2.9

37

15

0.006

TRV (m/sec)

Table I. Characteristics of Study Participants by History of Leg Ulcers, NIH Sickle Cell Cohort

No leg ulcers

History of leg ulcers

N

Median (IQR)a

N

Median (IQR)

P Valueb

Oxygen saturation (%)

242

98 (96–99)

45

96 (92–98)

0.01

Hemoglobin (g/dL)

309

9.8 (8.5–10.9)

69

8.2 (7.3–9.2)

<0.0001

Reticulocyte count (×10−3/µL)

299

207 (136–313)

68

278 (160.5–404)

0.003

Lactate dehydrogenase (U/L)

279

311 (288–405)

64

371.5 (274–497.5)

0.004

Aspartate aminotransferase (U/L)

306

35 (25–49)

68

41.5 (31.5–54)

0.02

Albumin (g/dL)

307

4.2 (3.8–4.4)

69

4.0 (3.7–4.2)

0.001

Alkaline phosphatase (IU/L)

308

87 (66–117)

68

97 (79–140)

0.02

Blood urea nitrogen (mg/dL)

308

7 (5–10)

68

8 (6–15.5)

0.01

Uric acid (mg/dL)

307

5.6 (4.5–7.0)

69

6.8 (4.8–8.3)

0.0004

NT-proBNP

259

58 (29–131)

59

132 (77–321)

<0.0001

Deaths, N (%)

295

25 (8.5)

68

14 (20.6)

Characteristic

•

a Except where otherwise noted.

•

b From Wilcoxon rank-sum test or Pearson Chi-square statistic between history of leg ulcer groups.

Figure 2. Kaplan–Meier survival curve by history of leg ulcers.

From this data, it is reasonable to conclude that sickle cell leg ulcers are a marker of disease severity. In patients
without SCD, high uric acid is identified as a possible cause of hypertension and a marker of risk for cardiovascular

disease, pulmonary hypertension, and early mortality. The epidemiological relationship between leg ulcers and
pulmonary hypertension supports an overlap of pathobiological mechanisms.
Genetic Modifiers of Sickle Cell Leg Ulcers
Twin studies have shown strong heritability of venous functions in humans and suggest that there may be genetic
modifiers that modulate the risk for leg ulcers in patients with sickle cell anemia [13]. This hypothesis is consistent
with the large patient to patient variability in developing this complication. However, the literature on genetic
associations with leg ulcer is very limited. We review results from candidate gene studies and then report preliminary
results of a genome-wide association study (GWAS) for an unbiased discovery of genetic modifiers of this phenotype.
Candidate Gene Studies
Limited results are available linking susceptibility to leg ulcer and genetic variants. A small study of 9 cases and 29
controls showed possible associations of HLA-B35 and CW14 alleles: the study showed that carriers of both alleles
increase the risk for the complication by 17 fold [14]. This study however was very small, and the region identified is
very difficult to study because of the long range linkage disequilibrium.
In a candidate gene study of 243 cases (aged 34.8 ± 12.5 years) and 516 controls (aged 30.7 ± 9.4 years) from the
CSSCD, Nolan et al. examined the associations of 250 single nucleotide polymorphisms (SNPs) in 60 candidate
genes that were selected for their putative role in the pathophysiology of sickle cell anemia [15]. The analysis found
associations with SNPs in Klotho, TEK, and several genes in the TGF-β/BMP signaling pathway by genotypic
association analyses [15]. KL directly or indirectly promotes endothelial NO production and the TEK receptor tyrosine
kinase is involved in angiogenesis. The TGF-β/BMP signaling pathway modulates wound healing and angiogenesis,
among its other functions. Some of the same SNPs were also associated with risk for stroke, priapism and pulmonary
hypertension [16–18]. The results are consistent with the observation that leg ulcer is associated with the intensity of
hemolytic anemia, and other subphenotypes of HbSS [11].
Genome-Wide Association Study
In the past few years, high-throughput technology has changed the field of human genetics. Commercial arrays can
be used to genotype up to 2M SNPs simultaneously and they allow for an unbiased screening of the a large number
of variants of the human genome [19]. We recently completed a GWAS of leg ulcer in almost 1,400 sickle cell anemia
patients from the CSSCD that included 219 leg ulcer cases and 1180 disease free subjects. We used innovative
statistical techniques to discover robust associations of both individual SNPs and genes with leg ulcer [19]. Single
SNP analysis identified 30 SNPs that are associated with leg-ulcer after we adjusted the analysis by age and gender.
The results included SNPs in ALCAM, supposed to regulate endothelial functions, and several SNPs in gene desert
regions. These associations with variants in gene-desert regions suggested that gene regulation may be involved
with the disease.

Because the study is underpowered, we also used a SNP-set analysis that, rather than looking at the association of
one SNP at a time, looks at the global associations of a set of SNPs. We showed that this approach has better power
to capture associations that individually do not meet genome-wide significance, but can point to region of interest
when they are analyzed as a group [20]. This analysis identified several genes that appear to be globally associated
with leg ulcer, and the full analysis will be reported elsewhere. Interestingly, this analysis showed that a cluster of
genes in the major histocompatibility complex class III region in chromosome 6 are strongly associated with leg ulcer.
This region is in strong linkage disequilibrium with the HLA-B complex that was linked to leg ulcers in the candidate
gene analysis of Ofosu et al. [14]. Furthermore, the same group of genes was found associated with increased
susceptibility to venous leg ulcer in older subjects who do not have SCD [14, 21].
Conclusions
These results are very preliminary and need to be followed by replication in independent studies to distinguish
between true positive and false positive associations, and then resequencing to target the functional variants that can
be used for treatment and development of risk prediction models. Because SCD is a rare disease in developed
countries, it is very difficult to find independent studies that can be used for replication and have a sufficiently large
sample size. A consortium of sickle cell anemia centers interested in genetic analysis, the SickleGen Consortium, is
being developed, to facilitate future collaborations.
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